BAUSCH + LOMB CORP (BLCO.CA) Stock Price, Quote, News and Overview
TSX:BLCO - Toronto Stock Exchange - CA0717051076 - Common Stock - Currency: CAD
BLCO.CA Quote, Performance and Key Statistics
BAUSCH + LOMB CORP
TSX:BLCO (2/12/2025, 7:00:00 PM)
23.53
+0.36 (+1.55%)
The current stock price of BLCO.CA is 23.53 CAD. In the past month the price decreased by -6.87%. In the past year, price increased by 18.46%.
BLCO.CA Latest News and Analysis
Bausch + Lomb Provides Update on Potential Sale
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2024 Financial Results on February 19
Bausch + Lomb Bolsters Pipeline with Acquisition of Whitecap Biosciences
Bausch + Lomb Launches enVista Aspire™ Intermediate Optimized Monofocal and Toric Intraocular Lenses in the European Union
Bausch + Lomb and Glaucoma Research Foundation Launch Second Annual “Faces of Glaucoma” Campaign and Fundraising Challenge
Bausch + Lomb to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
BLCO.CA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ZEN.CA | ZENTEK LTD | N/A | 160.22M | ||
| OTC.CA | OCUMETICS TECHNOLOGY CORP | N/A | 36.53M | ||
| COO.CA | OSTROM CLIMATE SOLUTIONS INC | N/A | 5.70M |
Related stock screener links
About BLCO.CA
Company Profile
Bausch + Lomb Corp. develops, manufactures, and markets eye health products. The company is headquartered in Vaughan, Ontario and currently employs 13,300 full-time employees. The company went IPO on 2022-05-06. The company operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
Company Info
BAUSCH + LOMB CORP
520 Applewood Crescent
Vaughan ONTARIO CA
Employees: 13300
Company Website: https://ir.bausch.com/
Investor Relations: https://ir.bausch.com/
Phone: 19082552864
BLCO.CA FAQ
What is the stock price of BLCO.CA?
The current stock price of BLCO.CA is 23.53 CAD.
What is the symbol for BAUSCH + LOMB CORP stock?
The exchange symbol of BAUSCH + LOMB CORP is BLCO and it is listed on the Toronto Stock Exchange exchange.
On which exchange is BLCO.CA stock listed?
BLCO.CA stock is listed on the Toronto Stock Exchange exchange.
Is BLCO.CA a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for BLCO.CA, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of BLCO.CA.
Does BLCO.CA stock pay dividends?
BLCO.CA does not pay a dividend.
When does BLCO.CA stock report earnings?
BLCO.CA will report earnings on 2025-02-19, after the market close.
What is the Price/Earnings (PE) ratio of BLCO.CA?
The PE ratio for BLCO.CA is 27.05. This is based on the reported non-GAAP earnings per share of 0.87 and the current share price of 23.53 CAD.
BLCO.CA Technical Analysis
BLCO.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to BLCO.CA. While BLCO.CA is still in line with the averages on profitability rating, there are concerns on its financial health.
BLCO.CA Financial Highlights
Over the last trailing twelve months BLCO.CA reported a non-GAAP Earnings per Share(EPS) of 0.87. The EPS decreased by -16.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -2.72% | ||
| ROE | -5.59% | ||
| Debt/Equity | 0.7 |
BLCO.CA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 73% to BLCO.CA. The Buy consensus is the average rating of analysts ratings from 20 analysts.
For the next year, analysts expect an EPS growth of -17.84% and a revenue growth 17.04% for BLCO.CA